Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

BIO is preparing small biotechs for life in the social media maelstrom

Last year the campaign for Chimerix to give an experimental cancer drug to a 7-year-old gave biopharma firms another reason to be wary of the power of social media. Having seen Chimerix be engulfed by the social media maelstrom, BIO is working to equip small biotechs with the skills they will need if they find themselves in a similar situation.

Gilead's John Martin scores 'best CEO' trophy for huge stock gains

U.S. CEO watchers can't get enough of Gilead Sciences chief John Martin. After catching bouquets from Harvard Business Review and a Tuck School of Business executive rater, Martin now wins the annual "best chief executive" trophy from investment firm Morningstar.

Rooting for a French CEO at Sanofi? Take another name off your list of prospects

Another purported Sanofi CEO candidate has publicly knocked himself off the list. Takeda chief operating officer and CEO-in-waiting Christophe Weber says he's not interested in the job. That makes two top pharma execs who've rebuffed the French drugmaker.

Bristol-Myers says COO Caforio to take over as CEO

Chief Operating Officer Giovanni Caforio will take over the top exec job at Bristol-Myers Squibb on May 5, when 64-year-old Lamberto Andreotti steps down from the role he has held for 5 years and takes over instead as executive chairman of the board.

MannKind COO Hakan Edstrom appointed CEO after founder steps down

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Salix CEO Logan steps down following inventory misstep

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Salix CEO takes a hike in latest fallout from inventory snafu

On Monday afternoon, CEO Carolyn Logan became the second C-suite executive at Salix Pharmaceuticals to step down in the wake of an inventory snafu disclosed late last year. Logan will retire as of Jan. 30, the company said.

'Crown prince' Schultz not a sure bet for Novo CEO as Sørensen's contract nears end

With Novo Nordisk's chief exec Lars Rebien Sørensen's contract expiring within the next few years, the company's board is scouting his replacement. And as soon as they name one, Sørensen says he's ready to make a quick exit.

Scientist Andy Plump steps in at Takeda as R&D chief

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Sanofi's Plump tapped to head Takeda R&D from Cambridge base

The new president at Takeda has raided Sanofi for its new head of global R&D. And they're putting their new top scientist in Cambridge, MA, which is becoming the world headquarters of drug research for much of the pharma industry.